
Phase II Trial of SMO/ AKT/ NF2/CDK Inhibitors in Progressive Meningiomas With SMO/ AKT/ NF2/CDK Pathway Mutations
Short Title: A071401
Enrollment Status: Recruiting
NCT #: NCT02523014
Specialty Area: Oncology
Conditions Studied: Intracranial Meningioma; Recurrent Meningioma; NF2 Gene Mutation
Age Groups: Adult; Older Adult
Phase: II
Study Information
Summary / Purpose
The purpose of this study is to see how well capivasertib and abemaciclib work in treating patients with meningioma that is growing, spreading, or getting worse (progressive). This trial is trying to see if tumor genetic testing would be helpful at guiding treatment.
Who Can Participate
- Adults 18+ years of age
- Must have histologically confirmed intracranial meningioma, progressive or residual disease
- Presence of SMO, PTCH1, NF2, CDKN2A, AKT1, PIK3CA, PTEN mutations, CDKN2A copy number loss, CDK4, CDK6, CCND1, CCND2, CCND3, or CCNE1 copy number gain in tumor sample
What's Involved
- Assignment to receive the study drug given orally
- Participate in follow up every 6 months for up to 5 years
Principal Investigator

Additional Information
Address: 1500 E 2nd St. Reno, NV 89502
General Research: 775-982-3646
Oncology Research: 775-982-5050
Email: Renown-CRD@renown.org
Complete Study Details: https://clinicaltrials.gov/study/NCT02523014
Disclaimer: This listing gives you general information about the study and isn't part of the official consent process. If you decide to learn more, the research team will talk with you and check if you meet any additional requirements to join the study.